Piper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK) Following 4Q16 Results
Tweet Send to a Friend
Piper Jaffray analyst Charles Duncan reiterates Overweight rating and $15 price target on Cytokinetics Inc. (NASDAQ: CYTK), suggesting the company’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
